Mesoblast has long been the one poster child for stem cell therapy. Now Cynata and other ASX stocks have emerged

· by · in Biotechnology industry, iPS Cells, Personalized Therapies, Regenerative Medicine. ·


Picture: The Flintstones (1960-), Hanna-Barbera Productions
https://stockhead.com.au/health/mesoblast-has-long-been-the-one-poster-child-for-stem-cell-therapy-now-cynata-and-other-asx-stocks-have-emerged/

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Google photo

You are commenting using your Google account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.